Symbols

NTRA

Natera·NASDAQ

--(--)

NTRA fundamentals

NTRA Q4 2025 Earnings

Natera (NTRA) released its earnings on Feb 26, 2026: revenue was 665.50M (YoY +39.78%), beat estimates; EPS was 0.36 (YoY +187.80%), beat estimates.

Revenue / YoY

665.50M

+39.78%

EPS / YoY

0.36

+187.80%

Report date

Feb 26, 2026

NTRA Earnings Call Summary for Q4,2025

Key Takeaways:

Revenue Growth: Q4 2025 revenue of $666 million (+40% YoY), with 2026 guidance of $2.62–$2.7 billion.
Gross Margin Expansion: Q4 gross margin 66.9%, 2026 target 63–65% driven by COGS savings and ASP gains.
Product Innovation: Launch of Latitude (tissue-free MRD) and Fetal Focus (21-gene NIPT) fueling growth. Phase variant technology enables ultra-sensitive MRD detection.
Strategic Investments: Japan launch in late 2026, R&D focus on early cancer detection, and clinical trials in new histologies.
Financial Strength: $1 billion cash, 2025 cash flow of $107 million, and 2026 OpEx growth of 9.5% at midpoint.

Earnings

EPS

Revenue

Revenue & Expenses

NTRA has released its 2025 Q4 earnings report, with revenue of 665.50M, reflecting a YoY change of 39.79%, and net profit of 47.26M, showing a YoY change of 187.89%. The Sankey diagram below clearly presents NTRA's revenue sources and cost distribution.

Key Indicators

Natera (NTRA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Natera (NTRA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Natera (NTRA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Natera (NTRA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown